363 related articles for article (PubMed ID: 32213992)
1. Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors.
Werner JM; Lohmann P; Fink GR; Langen KJ; Galldiks N
Molecules; 2020 Mar; 25(6):. PubMed ID: 32213992
[TBL] [Abstract][Full Text] [Related]
2. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?
Galldiks N; Langen KJ; Pope WB
Neuro Oncol; 2015 Nov; 17(11):1434-44. PubMed ID: 26130743
[TBL] [Abstract][Full Text] [Related]
3. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.
Albert NL; Weller M; Suchorska B; Galldiks N; Soffietti R; Kim MM; la Fougère C; Pope W; Law I; Arbizu J; Chamberlain MC; Vogelbaum M; Ellingson BM; Tonn JC
Neuro Oncol; 2016 Sep; 18(9):1199-208. PubMed ID: 27106405
[TBL] [Abstract][Full Text] [Related]
4. Amino Acid PET in Neurooncology.
Galldiks N; Lohmann P; Fink GR; Langen KJ
J Nucl Med; 2023 May; 64(5):693-700. PubMed ID: 37055222
[TBL] [Abstract][Full Text] [Related]
5. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
6. Current status of PET imaging in neuro-oncology.
Galldiks N; Lohmann P; Albert NL; Tonn JC; Langen KJ
Neurooncol Adv; 2019; 1(1):vdz010. PubMed ID: 32642650
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings.
Doi Y; Kanagawa M; Maya Y; Tanaka A; Oka S; Nakata N; Toyama M; Matsumoto H; Shirakami Y
Nucl Med Biol; 2015 Aug; 42(8):664-72. PubMed ID: 26022202
[TBL] [Abstract][Full Text] [Related]
8. Value of 11C-methionine PET in imaging brain tumours and metastases.
Glaudemans AW; Enting RH; Heesters MA; Dierckx RA; van Rheenen RW; Walenkamp AM; Slart RH
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):615-35. PubMed ID: 23232505
[TBL] [Abstract][Full Text] [Related]
9. Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know.
Soni N; Ora M; Jena A; Rana P; Mangla R; Ellika S; Almast J; Puri S; Meyers SP
AJNR Am J Neuroradiol; 2023 Mar; 44(3):236-246. PubMed ID: 36657945
[TBL] [Abstract][Full Text] [Related]
10. Molecular imaging (PET) of brain tumors.
Basu S; Alavi A
Neuroimaging Clin N Am; 2009 Nov; 19(4):625-46. PubMed ID: 19959009
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of positron emission tomographic studies for gliomas.
Miyake K; Ogawa D; Okada M; Hatakeyama T; Tamiya T
Neurol Med Chir (Tokyo); 2016 Jul; 56(7):396-408. PubMed ID: 27250577
[TBL] [Abstract][Full Text] [Related]
12. PET imaging in patients with brain metastasis-report of the RANO/PET group.
Galldiks N; Langen KJ; Albert NL; Chamberlain M; Soffietti R; Kim MM; Law I; Le Rhun E; Chang S; Schwarting J; Combs SE; Preusser M; Forsyth P; Pope W; Weller M; Tonn JC
Neuro Oncol; 2019 May; 21(5):585-595. PubMed ID: 30615138
[TBL] [Abstract][Full Text] [Related]
13. Phase IIa clinical study of [
Kondo A; Ishii H; Aoki S; Suzuki M; Nagasawa H; Kubota K; Minamimoto R; Arakawa A; Tominaga M; Arai H
Ann Nucl Med; 2016 Nov; 30(9):608-618. PubMed ID: 27418267
[TBL] [Abstract][Full Text] [Related]
14. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.
Galldiks N; Niyazi M; Grosu AL; Kocher M; Langen KJ; Law I; Minniti G; Kim MM; Tsien C; Dhermain F; Soffietti R; Mehta MP; Weller M; Tonn JC
Neuro Oncol; 2021 Jun; 23(6):881-893. PubMed ID: 33538838
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
16. Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[
Langen KJ; Stoffels G; Filss C; Heinzel A; Stegmayr C; Lohmann P; Willuweit A; Neumaier B; Mottaghy FM; Galldiks N
Methods; 2017 Nov; 130():124-134. PubMed ID: 28552264
[TBL] [Abstract][Full Text] [Related]
17. Facts and Fictions About [
Withofs N; Kumar R; Alavi A; Hustinx R
PET Clin; 2022 Jul; 17(3):327-342. PubMed ID: 35717096
[TBL] [Abstract][Full Text] [Related]
18. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
[TBL] [Abstract][Full Text] [Related]
19. Potential for differentiation of glioma recurrence from radionecrosis using integrated
Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
[TBL] [Abstract][Full Text] [Related]
20. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy.
Hirata T; Kinoshita M; Tamari K; Seo Y; Suzuki O; Wakai N; Achiha T; Umehara T; Arita H; Kagawa N; Kanemura Y; Shimosegawa E; Hashimoto N; Hatazawa J; Kishima H; Teshima T; Ogawa K
J Neurosurg; 2019 Sep; 131(3):676-686. PubMed ID: 30239314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
